Recent Updates
Recently added Catalysts

Clofarabine

Phase 1

Acute Myeloid Leukemia | Small molecule | Oncology |Bayer AG|Last Updated: Jan 12, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment44

FDA Designations

No designations recorded

Clinical trial landscape

Clofarabine · 1 trial · 5 indications

Phase 1 1
NCT00908167Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic MalignanciesAcute Myeloid Leukemia
COMPLETED44 Analytics
PHASE1COMPLETED
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
Acute Myeloid Leukemia
NCT0090816744
Unlock trial analytics

Study Endpoints

Primary Endpoints

To characterize a tolerable dose of sorafenib when given in combination with cytarabine and clofarabine in patients with relapsed/refractory hematologic malignancies.
4.5 years
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Research ParticipantsOTHERParticipants treated with sorafenib, cytarabine and clofarabine.

Interventions

NameTypeDescription
SorafenibDRUGPlease see detailed description.
CytarabineDRUGPlease see Detailed Description.
ClofarabineDRUGPlease see Detailed Description.
Unlock Study Design Details

Eligibility Criteria

Age RangeN/A to 31 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Patients must have a diagnosis of acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (either AML or ALL), AML with prior myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms, or biphe...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Clofarabine

What is Clofarabine used for in Acute Myeloid Leukemia?

Clofarabine is a small molecule being studied for use in Acute Myeloid Leukemia (AML). It is currently in Phase 1 clinical development as an investigational therapy. In a completed Phase 1 trial, it was evaluated in combination with cytarabine and sorafenib for patients with refractory or relapsed hematologic malignancies, including AML.

Who makes Clofarabine?

Clofarabine is being developed by Bayer AG, which trades under the ticker BAYRY. The company is conducting clinical research on this small molecule for the treatment of Acute Myeloid Leukemia, with the drug currently in Phase 1 development.

What phase is Clofarabine in?

Clofarabine is in Phase 1 clinical development for Acute Myeloid Leukemia. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains in early-stage clinical testing.

What clinical trials is Clofarabine in?

Clofarabine has one completed clinical trial registered as NCT00908167, titled "Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies." This Phase 1 study enrolled 44 participants in the United States and was not randomized or blinded.

Is Clofarabine the same as any other drug?

Clofarabine is a distinct small molecule drug and is not known by any alternative names. It is being investigated as a single agent, though in clinical trials it has been studied in combination with other drugs such as cytarabine and sorafenib for hematologic malignancies.